Loading
A midline is a longer drip tube put into a vein in the upper arm, with its tip still in the arm rather than near the heart. It avoids repeated needles, and it carries fewer bloodstream infections than a PICC. Whether it is safe for chemotherapy that can damage tissue if it leaks has not been settled.
A midline is a peripheral device: its tip lies in the upper arm or axillary vein, not in a central vein. CDC/HICPAC (2011) advises a midline or PICC instead of a short cannula when intravenous therapy will likely exceed six days (Category II), daily site checks, replacement only for a specific indication (II), and prompt removal when it is no longer essential (IA). The Italian SIMiC bundle (2026) sets seven insertion steps: ultrasound assessment of the arm and chest veins, choice of an upper-arm vein, hand hygiene, antisepsis and maximal barrier precautions, ultrasound-guided puncture, intra-procedural ultrasound tip location, sutureless securement and glue with a transparent dressing.
Against PICCs, a 2026 meta-analysis of 15 studies (over 27,000 patients) found PICCs had about four times the risk of catheter-related bloodstream infection (RR 4.18), with no difference in thrombosis, failure, occlusion or phlebitis; a second 2026 meta-analysis (29,680 catheters) found similar venous thromboembolism rates (3.5% against 3.8%). In cancer, a Japanese prospective study of 59 patients having continuous fluorouracil for at least four days found no phlebitis with a midline; and a systematic review found midlines and PICCs safe for symptom control in palliative care. The open question is vesicants: no guideline read says whether continuous or repeated vesicant chemotherapy may run through a midline, and the Japanese extravasation guideline cites a case report of oxaliplatin extravasation from one.
Why: A short cannula usually fails within days; a longer device avoids repeated needles.
“Use a midline catheter or peripherally inserted central catheter (PICC), instead of a short peripheral catheter, when the duration of IV therapy will likely exceed six days.”
CDC/HICPAC 2011 · Category II
Why: Each step lowers the chance of a failed attempt, an infection, a clot or the line falling out.
“The SIMiC bundle includes seven steps: (1) systematic ultrasound evaluation of the veins of the arms and the supra/infra-clavicular area; (2) choice of the most appropriate vein of the upper arm; (3) appropriate hand hygiene, proper skin antisepsis, and maximal barrier precautions; (4) ultrasound-guided venipuncture; (5) intra-procedural tip location, using infra/supraclavicular ultrasound scan; (6) sutureless securement, preferably using subcutaneous anchorage; (7) protection of the exit site with cyanoacrylate glue and semipermeable transparent membrane.”
Why: Early signs of infection, phlebitis or a leak are found by looking and feeling.
“Evaluate the catheter insertion site daily by palpation through the dressing to discern tenderness and by inspection if a transparent dressing is in use.”
CDC/HICPAC 2011 · Category II
Why: Routine replacement adds procedures without benefit.
“Replace midline catheters only when there is a specific indication.”
CDC/HICPAC 2011 · Category II
Why: Every day a line stays in adds to the risk of infection and clots.
“Promptly remove any intravascular catheter that is no longer essential [69–72].”
CDC/HICPAC 2011 · Category IA
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
Use a midline (or PICC) when intravenous therapy will likely exceed six days (CDC Category II), insert it with an ultrasound-guided bundle (SIMiC 2026), check it daily, replace it only for a reason (CDC II) and remove it promptly (CDC IA). Compared with PICCs, midlines carry fewer bloodstream infections and similar thrombosis risk (2026 meta-analyses). For anticancer drugs, the only cancer-specific evidence read is for continuous fluorouracil (Sakakida 2025); whether vesicants may be given through a midline is unresolved in the sources read, and the INS Standards that address it could not be read.
CDC/HICPAC 2011 · Journal of Vascular Access (GAVeCeLT and IVAS) 2026 · Frontiers in Cardiovascular Medicine (Aljameie et al.) 2026 · Thrombosis and Haemostasis (Santagata et al.) 2026 · The Oncologist (Sakakida et al.) 2025
Where it differs: Gives continuous fluorouracil over four days or more through an upper-arm midline with its tip in the axillary vein, instead of a short cannula or a central line.
Evidence: In a prospective Japanese study of 59 patients (mostly oesophageal and head and neck cancer), no phlebitis occurred (0%, 95% CI 0 to 6.2%), insertion succeeded in 98.3% and complications occurred in 6.8%; median dwell 5.5 days.
Where it differs: Uses a midline or PICC for weeks of intravenous symptom treatment or parenteral nutrition in people with advanced cancer.
Evidence: A systematic review of 17 studies (moderate or weak quality) found complications of 0 to 2.46 per 1,000 catheter days and high patient satisfaction.
Midline catheters, longer drips in the upper arm, carry fewer bloodstream infections than PICCs and are being used for chemotherapy. No guideline read says whether drugs that damage tissue if they leak can safely go through one.
Shares Catheter securement devices and dressings (SecurAcath, Tegaderm CHG), Choosing a venous access device for anticancer treatment: port, PICC, tunnelled line or cannula, Central venous catheter insertion for anticancer treatment: PICC, tunnelled line and implanted port, Infusion pumps, ports, and ambulatory chemotherapy devices.
Shares Central venous catheter insertion for anticancer treatment: PICC, tunnelled line and implanted port, Infusion pumps, ports, and ambulatory chemotherapy devices.
Shares Catheter securement devices and dressings (SecurAcath, Tegaderm CHG), Find out whether vesicant and irritant chemotherapy can safely run through a midline catheter, Choosing a venous access device for anticancer treatment: port, PICC, tunnelled line or cannula, Central venous catheter insertion for anticancer treatment: PICC, tunnelled line and implanted port.
Shares Peripheral cannula for anticancer treatment: vein choice, siting and checks, including vesicants, Find out whether vesicant and irritant chemotherapy can safely run through a midline catheter.
Shares Catheter securement devices and dressings (SecurAcath, Tegaderm CHG), Infusion pumps, ports, and ambulatory chemotherapy devices.
Shares Choosing a venous access device for anticancer treatment: port, PICC, tunnelled line or cannula, Central venous catheter insertion for anticancer treatment: PICC, tunnelled line and implanted port, Infusion pumps, ports, and ambulatory chemotherapy devices.
Shares Choosing a venous access device for anticancer treatment: port, PICC, tunnelled line or cannula, Central venous catheter insertion for anticancer treatment: PICC, tunnelled line and implanted port.
Shares Peripheral cannula for anticancer treatment: vein choice, siting and checks, including vesicants, Infusion pumps, ports, and ambulatory chemotherapy devices.